NeuBase Therapeutics’ CEO, Dietrich A. Stephan, Ph.D., to Present “Accelerating the Genetic Revolution with a New Class of Synthetic Medicines” at Tribe Public’s Event on December 22, 2020
Registration For This FREE Tribe Public Presentation and Q&A Event Is Now Open at NeuBase22.TribePublic.com
SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2020 / Tribe Public announced today that Dietrich Stephan, Ph.D., Chief Executive Officer of NeuBase Therapeutics, Inc. (NASDAQ:NBSE), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, will present at Tribe Public’s Presentation and Q&A Webinar Event beginning at 8:30 a.m. PDT / 11:30 a.m. EDT on Tuesday, December 22, 2020.
During this complimentary, 30-minute event, Dr. Stephan will deliver his presentation titled “Accelerating the Genetic Revolution with a New Class of Synthetic Medicines.” He will also be available for a brief Q&A session. To register for the complimentary event, please visit NeuBase22.TribePublic.com to reserve a seat for this limited capacity Zoom-based event.
Dietrich A. Stephan, Ph.D. is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Dr. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS, and Cell. In parallel, Dr. Stephan has founded or co-founded more than ten biotechnology companies and has advised numerous other companies. These companies are backed by top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures, as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Notably, Dr. Stephan founded NeuBase Therapeutics in August 2018, took it public in 2019, and has since grown the company to market capitalization to the tune of hundreds of millions of dollars. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his B.S. from Carnegie Mellon University.
ABOUT TRIBE PUBLIC LLC
Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe’s events focus on issues that the Tribe’s members care about with an emphasis on hosting management teams and experts from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress, and plans. Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell-Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribe’s FREE “Wish List” process. Visit Tribe Public’s Website www.tribepublic.com to join the Tribe and begin expressing your interests today.
ABOUT NEUBASE THERAPEUTICS, INC.
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
Tribe Public, LLC.
John F. Heerdink, Jr.
SOURCE: Tribe Public LLC
View source version on accesswire.com: